Key Highlights

  • Revenues were USD 380,216, against an estimate of USD 640 thousand.
  • Net loss per share was USD 0.12, narrower than the USD 0.14 loss expected.
  • Net loss widened to USD 1.38 million from USD 825,539.
  • Cash and cash equivalents were USD 3.63 million at September 30, 2026.

Revenue at 20/20 BioLabs (NASDAQ:AIDX) slipped in the third quarter of 2026 to USD 380,216, from USD 417,979 a year earlier, and landed well under the estimate of USD 640 thousand. The net loss was USD 1.38 million, compared with USD 825,539, yet the loss of USD 0.12 per common share on a basic and diluted basis was smaller than the USD 0.17 of the prior-year quarter and the estimated loss of USD 0.14.

After preferred stock dividends of USD 128,441, the net loss attributable to common stockholders was USD 1.50 million.

Margins and Expenses

Cost of revenues was USD 283,343, compared with USD 272,913, which left Gross Profit at USD 96,873, compared with USD 145,066. Sales, general and administrative expenses rose to USD 1.36 million from USD 814,179, while Research and Development expenses eased to USD 123,385 from USD 131,060.

Total operating expenses were USD 1.49 million, against USD 945,239, and the operating loss was USD 1.39 million, against USD 800,173. Interest income was USD 14,806, compared with USD 4,181, and total other income of USD 14,806 contrasted with total other expense of USD 25,366 a year before. Weighted average common shares outstanding were 12,958,114, compared with 4,849,770.

Nine Months to September 30

Over the nine months ended September 30, 2026, revenues were USD 1.46 million, compared with USD 1.51 million, and gross profit was USD 464,484, compared with USD 474,124. Sales, general and administrative expenses were USD 4.01 million, compared with USD 2.43 million, and research and development expenses were USD 534,499, compared with USD 462,015. The operating loss was USD 4.08 million, compared with USD 2.42 million.

Below the operating line, interest expense was USD 539,253, the loss on the change in Fair Value of the Warrant Liability was USD 148,766 and the loss on issuing a convertible note was USD 326,595. The net loss was USD 5.06 million, compared with USD 2.43 million. A deemed dividend of USD 1.12 million on warrant modifications and preferred stock dividends of USD 304,295 pushed the net loss attributable to common stockholders to USD 6.49 million, or USD 0.62 per share, compared with USD 0.50.

Cash Position and Going Concern Doubt

Cash and cash equivalents were USD 3,633,711 at September 30, 2026, compared with USD 1,025,987 at December 31, 2025, and the company reported Working Capital of USD 1,538,409. Accounts receivable, net, were USD 173,985. Total Assets were USD 5.02 million, compared with USD 4.14 million, and total current liabilities were USD 2.49 million. Total liabilities fell to USD 2.85 million from USD 4.16 million.

The filing discloses substantial doubt about the company's going concern status. It adds that planned activities may involve Equity raises and reverse stock splits.